30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

4Q13/2013 Revenue: Vexim

4Q13 revenue: €2.0MM (~US $2.7MM), +108%

  • >1,500 implantations of SpineJack in quarter (to date, ~9,000 implanted since launch)

 

2013 revenue: €6.1MM (~US $8.3MM), +123%

  • Direct sales 92% of total annual volume